Shigeru Miyagawa, Takuji Kawamura, Emiko Ito, Maki Takeda, Hiroko Iseoka, Junya Yokoyama, Akima Harada, Noriko Mochizuki-Oda, Yukiko Imanishi-Ochi, Junjun Li, Masao Sasai, Fumiyo Kitaoka, Masaki Nomura, Naoki Amano, Tomoko Takahashi, Hiromi Dohi, Eiichi Morii, Yoshiki Sawa
BACKGROUND: Cell- or tissue-based regenerative therapy is an attractive approach to treat heart failure. A tissue patch that can safely and effectively repair damaged heart muscle would greatly improve outcomes for patients with heart failure. In this study, we conducted a preclinical proof-of-concept analysis of the efficacy and safety of clinical-grade human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) patches. METHODS: A clinical-grade hiPSC line was established using peripheral blood mononuclear cells from a healthy volunteer that was homozygous for human leukocyte antigens...
March 13, 2024: Stem Cell Research & Therapy